Cancer Biomarkers

Cancer Biomarkers

The Cancer Biomarkers Research Group promotes research to identify, develop, and validate biological markers for early cancer detection and cancer risk assessment. Activities include development and validation of promising cancer biomarkers, collaborative databases and informatics systems, and new technologies or the refinement of existing technologies.

Read more About the Cancer Biomarkers Research Group.


Funding Opportunities

Active Grants


Adductomics Research Program (ARP)

This program promotes adducts/adductomics research-based strategies to identify a wide variety of molecular signatures for assessing risks, both exogenous and endogenous, as well as the combined effects to aid in optimization of cancer screening and prevention strategies

Learn more about the Adductomics Research Program

Alliance of Glycobiologists for Cancer Research

Tumor Glycomics Laboratories work to reveal cancer-related dynamics of complex carbohydrates.

Learn more about the Alliance of Glycobiologists for Cancer Research

Consortium for Imaging and Biomarkers (CIB)

Research Units integrate imaging strategies with biomarkers to improve cancer screening, early detection of aggressive cancer, assessment of cancer risk, and diagnosis of early stage cancer.

Learn more about the Consortium for Imaging and Biomarkers (CIB)

Consortium for Molecular Characterization of Screen-Detected Lesions

Seven laboratories and a coordinating center focus on identifying screening-detected pre-cancers and early cancers, including within the tumor microenvironment.

Read more about the Consortium for Molecular Characterization of Screen-Detected Lesions

Early Detection Research Network (EDRN)

Labs and centers bring together comprehensive infrastructure and resources critical to discovery, development and validation of biomarkers for cancer risk and early detection.

More about the Early Detection Research Network (EDRN)

Liquid Biopsy Consortium

A partnership with academic and industrial laboratory teams developing noninvasive liquid biopsy techniques to detect early stage cancer from biomarkers in blood, urine and sputum.

Learn more about the Liquid Biopsy Consortium

Pancreatic Cancer Detection Consortium (PCDC)

Research teams develop and test new molecular and imaging biomarkers to detect early stage pancreatic ductal adenocarcinoma and its precursor lesions.

Read more about the Pancreatic Cancer Detection Consortium (PCDC)

Program to Assess the Rigor and Reproducibility of Exosome-Derived Analytes for Cancer Detection

This program isolates and characterizes exosomes and their cargo for discovery of predictive biomarkers for risk assessment, detection, diagnosis and prognosis of early cancer.

Read more about this Program

Translational Liver Cancer (TLC) Consortium

Five Translational Research Centers conduct studies to improve surveillance of liver cancer in high-risk populations, increase detectability at early stages, and stratify at-risk patients.

Learn more about the Translational Liver Cancer (TLC) Consortium

New Technology Gives Patients Access to a 5-Minute, Office-Based Test to Identify Risk for Esophageal Cancer

A new technology coupled with a new biomarker test now in clinical trials are giving patients timely access to a quick, accurate and less invasive way to identify risk for one type of esophageal cancer. EsoCheck™ and EsoGuard™ are the device and test created for the detection of Barrett's esophagus, the benign and treatable precursor condition to esophageal adenocarcinomas (EAC).

New Onset Diabetes Cohort Sought to Unravel Complexities of Pancreatic Cancer Development

The National Cancer Institute is leading a project to create a cohort of people who are newly diagnosed with diabetes in the hopes that this group, who are at increased risk of developing pancreatic cancer, provide the clues in their blood and tissues to unravel some of the unknowns about this highly fatal cancer. The New Onset Diabetes Study (NOD) will include 10,000 people ages 50 to 85...